PMID- 35986246 OWN - NLM STAT- MEDLINE DCOM- 20220823 LR - 20220826 IS - 1471-2377 (Electronic) IS - 1471-2377 (Linking) VI - 22 IP - 1 DP - 2022 Aug 19 TI - The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study. PG - 304 LID - 10.1186/s12883-022-02841-9 [doi] LID - 304 AB - BACKGROUND: Neuropathic pain is a common complication in neuromyelitis optica spectrum disorder (NMOSD), which seriously affects the quality of life of NMOSD patients, with no satisfactory treatment. And risk factors of neuropathic pain are still uncertain. OBJECTIVE: To investigate the risk factors of neuropathic pain in a NMOSD cohort. MATERIALS AND METHODS: Our study was a retrospective case-cohort study, the patients diagnosed with NMOSD in the Department of Neurology from the Second Affiliated Hospital of Guangzhou University of Chinese Medicine from January 2011 to October 2021 were screened. Inclusion criteria were: (1) patients diagnosed as NMOSD according to the International Panel for NMO Diagnosis (IPND) criteria, (2) the aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) test was performed. Patients without AQP4-IgG antibody were excluded. Clinical data, including sex, age of the first onset, symptoms of the first episode including neuropathic pain and attack types, localization of lesions of the first episode on Magnetic Resonance Imaging (MRI), Extended disability status Scale (EDSS) of the first onset, treatment of immunosuppression in the first acute phase, disease modifying therapy (DMT), treatment of neuropathic pain and APQ4-IgG status were collected from the hospital system database. Neuropathic pain was defined according to the International Association for the Study of Pain criteria and was described as "pain arising as a direct consequence of a lesion or disease affecting the somatosensory system". RESULTS: One hundred nineteen patients were screened and finally 86 patients fulfilling the inclusion and exclusion criteria were enrolled in our study. The prevalence of neuropathic pain in patients with NMOSD was 43.0%. Univariate analysis showed that the factors associated with neuropathic pain were the age at the onset, the attack type of optic neuritis, the attack type of myelitis, length of spinal cord involvement, localization of thoracic lesion, optic lesion, upper thoracic lesions, lower thoracic lesions, extended spinal cord lesions (>/= 3 spinal lesions), extended thoracic lesions (>/= 4 thoracic lesions), intravenous immunoglobulin and mycophenolate mofetil. Multivariate regression analysis showed that extended thoracic lesions (OR 20.21 [1.18-346.05], P = 0.038) and age (OR 1.35 (1-1.81) P = 0.050) were independently associated with neuropathic pain among NMOSD patients and that gender (OR 12.11 (0.97-151.64) P = 0.053) might be associated with neuropathic pain among NMOSD patients. CONCLUSION: Extended thoracic lesions (>/= 4 thoracic lesions), age and gender might be independent risk factors of neuropathic pain among patients with NMOSD. However, with a small sample size and predominantly female, caution must be applied and these results need validating in further cohorts. CI - (c) 2022. The Author(s). FAU - Li, Xiaojun AU - Li X AD - The Second Clinical College of Guangzhou, University of Chinese Medicine, Guangzhou, 510006, China. FAU - Xu, Haoyou AU - Xu H AD - Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 111 Dade Road, Guangzhou, 510120, China. FAU - Zheng, Zequan AU - Zheng Z AD - Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 111 Dade Road, Guangzhou, 510120, China. FAU - Ouyang, Huiying AU - Ouyang H AD - The Second Clinical College of Guangzhou, University of Chinese Medicine, Guangzhou, 510006, China. FAU - Chen, Guixian AU - Chen G AD - The Second Clinical College of Guangzhou, University of Chinese Medicine, Guangzhou, 510006, China. FAU - Lou, Zhenzhen AU - Lou Z AD - The Second Clinical College of Guangzhou, University of Chinese Medicine, Guangzhou, 510006, China. FAU - Chen, Haoxuan AU - Chen H AD - The Second Clinical College of Guangzhou, University of Chinese Medicine, Guangzhou, 510006, China. FAU - Zhang, Jiahui AU - Zhang J AD - Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 111 Dade Road, Guangzhou, 510120, China. FAU - Zhan, Yibo AU - Zhan Y AD - The Second Clinical College of Guangzhou, University of Chinese Medicine, Guangzhou, 510006, China. FAU - Mao, Hui AU - Mao H AD - The Second Clinical College of Guangzhou, University of Chinese Medicine, Guangzhou, 510006, China. FAU - Zhang, Changlin AU - Zhang C AD - The Second Clinical College of Guangzhou, University of Chinese Medicine, Guangzhou, 510006, China. FAU - Zhao, Min AU - Zhao M AD - Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 111 Dade Road, Guangzhou, 510120, China. 376479808@qq.com. FAU - Zhao, Yuanqi AU - Zhao Y AD - Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 111 Dade Road, Guangzhou, 510120, China. tcm2008@126.com. LA - eng PT - Journal Article DEP - 20220819 PL - England TA - BMC Neurol JT - BMC neurology JID - 100968555 RN - 0 (Aquaporin 4) RN - 0 (Autoantibodies) RN - 0 (Immunoglobulin G) SB - IM MH - Aquaporin 4 MH - Autoantibodies MH - Cohort Studies MH - Female MH - Humans MH - Immunoglobulin G MH - Male MH - *Neuralgia/epidemiology MH - *Neuromyelitis Optica/complications/diagnosis/epidemiology MH - Quality of Life MH - Retrospective Studies MH - Risk Factors PMC - PMC9389678 OTO - NOTNLM OT - AQP4-IgG antibody OT - Neuromyelitis optica spectrum disorder OT - Neuropathic pain COIS- The authors declare that there is no conflict of interest. EDAT- 2022/08/20 06:00 MHDA- 2022/08/24 06:00 PMCR- 2022/08/19 CRDT- 2022/08/19 23:31 PHST- 2022/04/23 00:00 [received] PHST- 2022/08/10 00:00 [accepted] PHST- 2022/08/19 23:31 [entrez] PHST- 2022/08/20 06:00 [pubmed] PHST- 2022/08/24 06:00 [medline] PHST- 2022/08/19 00:00 [pmc-release] AID - 10.1186/s12883-022-02841-9 [pii] AID - 2841 [pii] AID - 10.1186/s12883-022-02841-9 [doi] PST - epublish SO - BMC Neurol. 2022 Aug 19;22(1):304. doi: 10.1186/s12883-022-02841-9.